tiprankstipranks
Imago BioSciences presents data from ongoing Phase 2 study of bomedemstat
The Fly

Imago BioSciences presents data from ongoing Phase 2 study of bomedemstat

Imago BioSciences presented positive data from its ongoing global Phase 2 clinical study evaluating bomedemstat in patients with advanced myelofibrosis. The data were presented in a poster presentation session during the 64th American Society of Hematology Annual Meeting and Exposition taking place 10-13 December 2022. A Phase 2 data set with a cut-off date of 29 April 2022 was previously presented at the 30th European Hematology Association Annual Meeting and congress in June 2022 Updated Highlights: Of evaluable patients at 24 weeks: 65% showed a decrease in Total Symptom Score. 19% showed a greater than or equal to 50% decrease in TSS. 66% showed spleen volume reductions from baseline. 28% showed a greater than or equal to 20% spleen volume reduction. The majority of patients had a decrease in mutant allele frequencies including driver mutations and high molecular risk mutations/ 90% of transfusion-independent patients had stable or improved hemoglobin at Week 12. 85% of patients had an improved or stable bone marrow fibrosis score post-baseline. No new mutations or transformations to acute myeloid leukemia while on treatment, even in patients with a high-risk of progression. Bomedemstat was generally safe and well-tolerated in patients with myelofibrosis. The most common non-hematologic adverse event related to bomedemstat was dysgeusia, which occurred in 33% of patients and led to discontinuation of the study in 1 patient. There were 44 patients who reported a total of 86 serious adverse events, 16% of which were deemed drug-related by the investigator.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on IMGO:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles